A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Trial Profile

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2018

At a glance

  • Drugs AG 10 (Primary)
  • Indications Amyloidosis; Cardiomyopathies
  • Focus Adverse reactions
  • Sponsors Eidos Therapeutics
  • Most Recent Events

    • 20 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 03 May 2018 According to an Eidos Therapeutics media release, the first patient has been dosed in this trial and the company expects to report top-line results by the end of 2018.
    • 26 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top